Sugi Predict

Sugi Predict / Compounds / SCHEMBL17931727

SCHEMBL17931727

SCHEMBL17931727

CC[C@H](C)[C@H](NC(=O)C(CS)NC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NC(Cc1cnc[nH]1)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@H](C=O)CO)[C@@H](C)O

nearest known ligand 0.54

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 2/20 0.54
▸ RAMP3 O60896 12/20 0.54
▸ CALCR P30988 12/20 0.54
▸ NPY2R P49146 5/20 0.52
▸ NPY4R P50391 5/20 0.52
▸ NPY5R Q15761 5/20 0.52
▸ NPY1R P25929 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362916 0.87 NPY2R (0.61) CXCR4RAMP3CALCRNPY2RNPY4R
SCHEMBL29427727 0.78 PTPN1 (0.58) RAMP3CALCRNPY2RNPY4RNPY5R
SCHEMBL15381927 0.77 RAMP3 (0.54) CXCR4RAMP3CALCR
SCHEMBL13120983 0.76 REN (0.53) CXCR4RAMP3CALCR
SCHEMBL268375 0.76 CALCR (0.85) CALCRNPY2RNPY4RNPY5RNPY1R
SCHEMBL29724165 0.75 CXCR4 (0.60) CXCR4RAMP3CALCRNPY2RNPY4R
SCHEMBL31182855 0.75 CALCR (0.65) CXCR4CALCR
SCHEMBL31182460 0.75 CALCR (0.69) CALCRNPY2RNPY4RNPY5RNPY1R
SCHEMBL30432915 0.75 CALCRL (0.50) CALCRNPY2RNPY4RNPY5RNPY1R
SCHEMBL29614957 0.75 TFPI (0.63) CXCR4RAMP3CALCRNPY2RNPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010580-B2 Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptide LEVETAN CLARESA (US) 2018-07-03 — — US disclosed
US-10010577-B2 Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide LEVETAN CLARESA (US) 2018-07-03 — — US disclosed
US-20160213746-A1 INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE LEVETAN CLARESA (US) 2016-07-28 — — US disclosed
US-20160206682-A1 INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE LEVETAN CLARESA (US) 2016-07-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10010577-B2 Insulin independence among patients with diabetes utilizing an optimized hamster REG3 gamma peptide IAPP, GLP1R, AMY2A CXCR4 700/4885RAMP3 52/4885CALCR 1384/4885
US-20160213746-A1 INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE IAPP, GLP1R, AMY2A CXCR4 700/4885RAMP3 52/4885CALCR 1384/4885
US-10010580-B2 Insulin independence among patients with diabetes utilizing an optimized hamster Reg3 gamma peptide IAPP, GLP1R, AMY2A CXCR4 700/4885RAMP3 52/4885CALCR 1384/4885
US-20160206682-A1 INSULIN INDEPENDENCE AMONG PATIENTS WITH DIABETES UTILIZING AN OPTIMIZED HAMSTER REG3 GAMMA PEPTIDE IAPP, GLP1R, AMY2A CXCR4 700/4885RAMP3 52/4885CALCR 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback